I

    Immunic Inc (IMUX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.80
    +0.40 (+2.60%)

    Market Cap: $210.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -45.77%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.18
    Range$-2.21 - $-0.68
    10 analysts
    EPS Revisions
    3
    0
    7d
    2
    4
    30d
    EPS Estimate Drift
    90d ago$-1.08+8.3%
    60d ago$-1.19-1.0%
    30d ago$-1.19-1.0%
    7d ago$-1.19-1.0%
    Current$-1.18
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.38
    Range$-2.42 - $0.21
    11 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-1.18---
    Jun 26
    		$-0.80$-1.24+35.48%Beat-300.0%
    Mar 26
    		$-1.08$-0.96-12.50%Miss-332.0%
    Dec 25
    		$-0.12$-0.10-20.00%Miss+95.2%
    Sep 25
    		$-1.30$-1.77+26.55%Beat+45.8%
    Jun 25
    		$-0.20$-0.18-11.11%Miss+90.5%
    Mar 25
    		$-0.25$-0.25+0.00%Beat+91.7%
    Dec 24
    		$-2.50$-2.38-5.04%Miss-420.8%
    Sep 24
    		$-2.40$-2.18-10.09%Miss+52.9%
    Jun 24
    		$-2.10$-2.33+9.87%Beat+61.1%
    Mar 24
    		$-3.00$-2.65-13.21%Miss+48.3%
    Dec 23
    		$-0.48$-0.51+5.88%Beat+91.8%
    Sep 23
    		$-5.10$-5.07-0.59%Miss+26.1%
    Jun 23
    		$-5.40$-5.12-5.47%Miss+25.0%
    Mar 23
    		$-5.80$-4.80-20.83%Miss+21.6%
    Dec 22
    		$-5.88$-7.42+20.75%Beat-716.7%
    Sep 22
    		$-6.90$-6.95+0.72%Beat+9.2%
    Jun 22
    		$-7.20$-7.30+1.37%Beat+12.2%
    Mar 22
    		$-7.40$-7.57+2.25%Beat+9.1%
    Dec 21
    		$-0.72$-0.76+5.26%Beat-56.5%
    Sep 21
    		$-7.60$-7.52-1.06%Miss-8.6%
    Jun 21
    		$-8.20$-6.67-22.94%Miss+8.9%
    Mar 21
    		$-8.14$-6.85-18.83%Miss-930.4%
    Dec 20
    		$-0.46$-0.60+23.33%Beat+93.9%
    Sep 20
    		$-7.00$-6.47-8.19%Miss+14.6%
    Jun 20
    		$-9.00$-7.27-23.80%Miss+40.8%
    Mar 20
    		$-0.79$-0.95+16.84%Beat+12.7%
    Dec 19
    		$-7.50$-7.60+1.32%Beat-212.5%
    Sep 19
    		$-8.20$-6.50-26.15%Miss+26.8%
    Jun 19
    		$-15.20$-6.80-123.53%Miss-26.7%
    Mar 19
    		$-0.91$-0.59-53.39%Miss+93.3%
    Dec 18
    		$-2.40$-0.14-1614.29%Miss+82.9%
    Sep 18
    		$-11.20$-11.20+0.00%Beat+6.7%
    Jun 18
    		$-12.00$-13.20+9.09%Beat-3.4%
    Mar 18
    		$-13.60$-13.60+0.00%Beat+12.8%
    Dec 17
    		$-14.00$-12.40-12.90%Miss+5.4%
    Sep 17
    		$-12.00$-12.80+6.25%Beat+6.3%
    Jun 17
    		$-11.60$-14.13+17.91%Beat-
    Mar 17
    		$-15.60$-14.60-6.85%Miss-
    Dec 16
    		$-14.80$-14.20-4.23%Miss-
    Sep 16
    		$-12.80$-12.96+1.23%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.79EV/EBITDA0.21x
    Price/FCF-7.63xFCF Yield-13.11%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-138.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.05xQuick Ratio5.05x
    Trading Statistics
    Beta1.40Avg Volume191.54K
    52-Week High$17.4352-Week Low$5.06

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.28
    SMA 20$15.70
    SMA 50$15.07
    SMA 200$10.90
    EMA 10$16.01
    EMA 20$15.73
    EMA 50$14.95
    EMA 200$12.17

    MACD

    Line: 0.41Signal: 0.48Hist: -0.07

    ADX

    ADX: 27.8+DI: 18.1-DI: 17.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$17.27

    Bollinger Bands

    Upper Band$17.62
    Lower Band$13.77
    %B Position2449%(Upper)
    Band Width0.53

    RSI (14-Day)

    Neutral
    52.7

    Momentum Oscillators

    Stoch %K48.7
    Stoch %D61.0
    Williams %R-67.1
    ROC (10d)-1.4%
    Momentum-0.23
    CCI (20d)-4.0
    MFI (14d)57.1

    Volatility Measures

    ATR (14d)$0.99(6.3%)
    StdDev (20d)0.96
    Hist Vol55.0%(High)

    Volume Flow

    VWAP$15.66
    OBV25.3M
    AD Line110.1B
    CMF (20d)-0.079

    Volume Metrics

    Avg Vol (20d)192.6K
    Vol Ratio0.6x
    VWMA (20d)$15.67

    Pivot Points

    R3$17.43
    R2$16.87
    R1$16.13
    Pivot Point$15.57
    S1$14.83
    S2$14.27
    S3$13.53

    Advanced Oscillators

    TSI15.78
    Ultimate Osc48.4
    KST124.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$114,000$0$0$0$0$0
    Cost of Revenue$0$0$42,000$0$0$0$35,000$0$0$0$23,000$0
    Gross Profit$0$0$-42,000$0$0$0$-35,000$0$0$0$-23,000$0
    Operating Expenses$35.33M$33.23M$23.33M$25.99M$27.08M$26.82M$25.63M$25.73M$22.81M$23.88M$23.38M$23.57M
    R&D$25.93M$25.63M$19.07M$20.01M$21.37M$21.53M$21.62M$21.37M$18.32M$18.74M$19.28M$19.80M
    SG&A$9.40M$7.61M$4.26M$5.98M$5.71M$5.29M$4.01M$4.36M$4.49M$5.14M$4.10M$3.77M
    Operating Income$-35,327,000$-33,235,000$-23,327,000$-25,993,000$-27,083,000$-26,825,000$-25,631,000$-25,726,000$-22,814,000$-23,881,000$-23,381,000$-23,570,000
    Interest Income$1.29M$760,000$197,000$419,000$241,000$183,000$429,000$776,000$998,000$1.19M$541,000$766,000
    Interest Expense$0$0$0$0$0$0$0$0$0$5.70M$0$0
    Income Before Tax$-34,099,000$-32,588,000$-19,300,000$-25,579,000$-26,820,000$-25,473,000$-25,175,000$-24,368,000$-21,380,000$-29,584,000$-21,572,000$-22,769,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-34,099,000$-32,588,000$-19,300,000$-25,579,000$-26,820,000$-25,473,000$-25,175,000$-24,368,000$-21,380,000$-29,584,000$-21,572,000$-22,769,000
    EBITDA$-35,351,000$-33,315,000$-19,455,000$-25,958,000$-27,018,000$-25,613,000$-25,569,000$-25,102,000$-22,347,000$-30,745,000$-22,090,000$-23,501,000
    EBIT$-35,385,000$-33,348,000$-19,497,000$-25,998,000$-27,061,000$-25,656,000$-25,604,000$-25,144,000$-22,378,000$-30,771,000$-22,113,000$-23,535,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMUX

    News

    Immunic (IMUX) Institutional Ownership 2026

    This article details the institutional ownership of Immunic (NASDAQ:IMUX) as of 2026, showing that 51.82% of its stock is held by institutional investors. It provides a breakdown of institutional buying and selling over the last two years, including the largest shareholders and transaction volumes. Key institutional investors include Braidwell LP, Avidity Partners Management LP, and Aberdeen Group plc.

    MarketBeat•8/22/26•
    Neutral

    EBITDA per share of Immunic, Inc. – HAM:10V

    This article provides financial information for Immunic, Inc. (HAM:10V) on TradingView, specifically focusing on its EBITDA per share. It is presented as a snapshot of the company's financial data on the Hamburg Stock Exchange.

    TradingView•8/20/26•
    Neutral

    Discontinued operations of Immunic, Inc. – HAM:10V

    The article reports on the discontinued operations of Immunic, Inc., traded on the Hamburg Stock Exchange under the ticker HAM:10V. It notes that the market is currently closed with no trades recorded. The content is primarily a financial data listing for the company.

    TradingView•8/19/26•
    Bearish

    Long term debt to total assets ratio of Immunic, Inc. – HAM:10V

    This article focuses on the long-term debt to total assets ratio for Immunic, Inc. (HAM:10V). It appears to be a financial data point provided by TradingView, indicating a specific financial metric for the pharmaceutical company. The content itself is very minimal, serving primarily as a placeholder for financial data that would typically be displayed on a platform like TradingView.

    TradingView•8/19/26•
    Neutral

    Wedbush initiates Immunic stock with Outperform rating By Investing.com

    Wedbush has initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating and a $45.00 price target, highlighting the company's lead drug vidofludimus calcium for multiple sclerosis. Immunic holds more cash than debt and has a strong current ratio, supporting its clinical development. The company has also recently appointed Erik Lundgren as its new CEO, signaling a potential shift towards commercialization.

    Investing.com Australia•8/17/26•
    Bullish

    Frequently Asked Questions About IMUX

    Does IMUX pay dividends?
    Immunic Inc (IMUX) does not currently pay a regular dividend.
    What is IMUX's market cap?
    Immunic Inc (IMUX) has a market capitalization of $210.13M with a current stock price of $15.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In